BioMarin Announces Data Analysis Demonstrating Consistent Efficacy of Kyndrisa™ (drisapersen) in Comparable Patients Across Three Randomized Studies
November 20, 2015 08:11 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Nov. 20, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced data analysis for Kyndrisa demonstrating consistent evidence of efficacy in...
FDA Posts Briefing Documents for Advisory Committee Meeting to Review Kyndrisa™ (drisapersen) for the Potential Treatment of Duchenne Muscular Dystrophy Amendable to Exon 51 Skipping
November 20, 2015 08:10 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Nov. 20, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that the U.S. Food and Drug Administration (FDA) posted briefing materials...
Ernst & Young Names BioMarin CEO Jean-Jacques Bienaime EY Entrepreneur Of The Year® 2015 National Award Winner in Life Sciences
November 16, 2015 08:00 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Nov. 16, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Ernst & Young Global Limited awarded BioMarin CEO Jean-Jacques Bienaimé...
BioMarin to Attend Upcoming Investor Conference in November
October 27, 2015 08:30 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Oct. 27, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate...